Physician profile

Mark D Miller

Family Medicine · Kilgore, TX

NPI 1609840388

$284.44

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$67.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Sanofi-Aventis U.S. LLC $58.54 2019
Acclarent, INC $41.47 2023 Trudi Nav Cable
Glaxosmithkline, LLC. $34.11 2019
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $32.84 2019-2020
Regeneron Healthcare Solutions, INC. $25.53 2024 Dupixent
Takeda Pharmaceuticals U.S.A., INC. $23.61 2019
Boehringer Ingelheim Pharmaceuticals, INC. $22.66 2019
Novo Nordisk INC $16.65 2019
Kls-Martin L.P. $14.98 2019
Amgen INC. $14.05 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark D Miller

$284.44

in general payments reported 2019-2025

Years
2019-2024
Top company
Sanofi-Aventis U.S. LLC

https://glasscript.com/doctor/163016/mark-d-miller

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.